17 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp05743 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 0.1.4% cell growth inhibition at 160 µM |
| dbacp05744 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05745 | PTPRJ-pep19.0 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05746 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 16.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05747 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 30 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05748 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 32.0 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05749 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 28 ± 5.5% cell growth inhibition at 160 µM |
| dbacp05750 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 46 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05751 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 51 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05752 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 48.0 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05753 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 62.5 ± 4.9% cell growth inhibition at 160 µM |
| dbacp05754 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 66.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05755 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 2 ± 1.5% cell growth inhibition at 160 µM |
| dbacp05756 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05757 | PTPRJ-pep19.6 | CHHNLAHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05758 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 2.13% cell growth inhibition at 160 µM |
| dbacp05759 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 20 ± 1.4% cell growth inhibition at 160 µM |